Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer. The Company is developing new drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. One of these agents is an oral immune checkpoint inhibitor that has been through human safety testing where it demonstrated favorable safety and pharmacologic properties. It recently entered cancer clinical trials.

Type
Public
HQ
Burlingame, US
Founded
2014
Size (employees)
44 (est)
Corvus Pharmaceuticals was founded in 2014 and is headquartered in Burlingame, US
Report incorrect company information

Key People/Management at Corvus Pharmaceuticals

Richard Miller

Richard Miller

Co-Founder, President and CEO
Joseph Buggy

Joseph Buggy

Co-Founder and Executive Vice President, Discovery Research
Daniel W. Hunt J.D

Daniel W. Hunt J.D

Senior Vice President and Chief Business Officer
Leiv Lea

Leiv Lea

CFO
James Janc

James Janc

Vice President, Pharmacology
William Jones

William Jones

Vice President, Pharmaceutical Development
Show more

Corvus Pharmaceuticals Office Locations

Corvus Pharmaceuticals has an office in Burlingame
Burlingame, US (HQ)
102 863 Mitten Rd
Show all (1)
Report incorrect company information

Corvus Pharmaceuticals Financials and Metrics

Corvus Pharmaceuticals Financials

USD

Net income (Q1, 2018)

(14.3 m)

EBIT (Q1, 2018)

(14.6 m)

Market capitalization (14-Jun-2018)

378.6 m

Closing share price (14-Jun-2018)

13

Cash (31-Mar-2018)

102.6 m
Corvus Pharmaceuticals's current market capitalization is $378.6 m.
Annual
USDFY, 2016

General and administrative expense

123 k

R&D expense

38 k

Operating expense total

161 k

EBIT

(161 k)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

General and administrative expense

2.8 m2.7 m2.8 m2.5 m

R&D expense

7.7 m13.5 m12.4 m12.1 m

Operating expense total

10.5 m16.2 m15.2 m14.6 m

EBIT

(10.5 m)(16.2 m)(15.2 m)(14.6 m)
USDQ1, 2016Q2, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

4.1 m4.3 m10.5 m34.1 m102.6 m

Current Assets

154.1 m153.5 m123.1 m111.6 m145.2 m

PP&E

2.6 m2.8 m3.1 m3 m2.5 m

Total Assets

157.2 m156.9 m127.1 m115.5 m148.7 m
Annual
USDFY, 2016

Net Income

(161 k)

Accounts Payable

1.9 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(6.3 m)(15 m)(10.3 m)(16 m)(14.3 m)

Depreciation and Amortization

106 k250 k219 k

Accounts Payable

(193 k)129 k2.4 m2.4 m45 k

Cash From Operating Activities

(5.6 m)(11.8 m)(11 m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Corvus Pharmaceuticals Operating Metrics

Corvus Pharmaceuticals's Patent Applications was reported to be 11 in FY, 2016.
FY, 2016

Patent Applications

11

Patents Licensed

18
Show all operating metrics
Report incorrect company information

Corvus Pharmaceuticals News and Updates

Report incorrect company information